News on Our portfolioApril 1, 20210Completion of a £6 million fundraise for Biosceptre International.
Norcliffe Capital are pleased to announce the completion of a £6 million fundraise for Biosceptre International. Biosceptre International are developing groundbreaking CAR T cancer therapeutics with a unique target that is only found on cancer cells, not normal cells, that should mitigate the usual side effects associated with cancer treatments. Biosceptre is such an exciting...